Search

Your search keyword '"Mezzabotta, Lavinia"' showing total 44 results
Start Over Author "Mezzabotta, Lavinia"
44 results on '"Mezzabotta, Lavinia"'

6. Peripheral Insulin Resistance Predicts Liver Damage in Nondiabetic Subjects With Nonalcoholic Fatty Liver Disease

Author

Rosso, Chiara, Mezzabotta, Lavinia, Gaggini, Melania, Salomone, Federico, Gambino, Roberto, Marengo, Andrea, Saba, Francesca, Vanni, Ester, Jouness, Rami I.K., Saponaro, Chiara, Buzzigoli, Emma, Caviglia, Gian Paolo, Abate, Maria Lorena, Smedile, Antonina, Rizzetto, Mario, Cassader, Maurizio, Gastaldelli, Amalia, and Bugianesi, Elisabetta

Published
2016
Full Text
View/download PDF

10. Metabolomic analysis identifies new biomarkers of liver damage in NAFLD: 60

Author

Vanni, Ester, Rosso, Chiara, Mezzabotta, Lavinia, Sapon-aro, Chiara, Gaggini, Melania, Gambino, Roberto, Kamal Jouness, Ramy Ibrahim, Saba, Francesca, Buzzigoli, Emma, Carli, Fabrizia, Caviglia, Gian Paolo, Abate, Maria Lorena, Smedile, Antonina, Rizzetto, Mario, Cassader, Maurizio, Gastaldelli, Amalia, and Bugianesi, Elis-abetta

Published
2014

13. IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis

Author

Eslam, Mohammed, McLeod, Duncan, Kelaeng, Kebitsaone Simon, Mangia, Alessandra, Berg, Thomas, Thabet, Khaled, Irving, William, Dore, Gregory J., Sheridan, David, Grønbæk, Henning, Abate, María Lorena, Hartmann, Rune, Bugianesi, Elisabetta, Spengler, Ulrich, Rojas Álvarez-Ossorio, M. Ángeles, Booth, David R., Weltman, Martin, Mollison, Lindsay, Cheng, Wendy, Riordan, Stephen, Mahajan, Hema, Fischer, Janett, Nattermann, Jacob, Douglas, Mark W., Liddle, Christopher, Powell, Elizabeth, Romero-Gómez, Manuel, George, Jacob, Metwally, Mayada, White, Rosa, Gallego-Durán, Rocío, Leung, Reynold, Mahajan, Neha, Bassendine, Margaret, Rahme, Antony, Rosso, Chiara, Mezzabotta, Lavinia, Malik, Barbara, Matthews, Gail, Asimakopoulos, Anastasia, Applegate, Tanya, Grebely, Jason, Fragomeli, Vicenzo, Jonsson, Julie R., Santoro, Rosanna, Sydney Medical Foundation, University of Sydney, and National Health and Medical Research Council (Australia)

Subjects
0301 basic medicine, LAMBDA 4, Genotype, health care facilities, manpower, and services, education, Inflammation, Hepacivirus, LIVER FIBROSIS, GENOME-WIDE-ASSOCIATION, Biology, Polymorphism, Single Nucleotide, Linkage Disequilibrium, INTERFERON-STIMULATED GENES, 03 medical and health sciences, Immune system, Gene Frequency, Fibrosis, INFECTION, Genetics, medicine, Humans, HCV CLEARANCE, SNP, C VIRUS, health care economics and organizations, Hepatitis, Reverse Transcriptase Polymerase Chain Reaction, Interleukins, Haplotype, medicine.disease, Hepatitis C, Phenotype, III INTERFERONS, Logistic Models, 030104 developmental biology, Haplotypes, Liver, Multivariate Analysis, Immunology, SOLID-ORGAN, Interferons, medicine.symptom, IL28B GENE
Abstract

The International Liver Disease Genetics Consortium (ILDGC)., Genetic variation in the IFNL3–IFNL4 (interferon-λ3–interferon-λ4) region is associated with hepatic inflammation and fibrosis1,2,3,4. Whether IFN-λ3 or IFN-λ4 protein drives this association is not known. We demonstrate that hepatic inflammation, fibrosis stage, fibrosis progression rate, hepatic infiltration of immune cells, IFN-λ3 expression, and serum sCD163 levels (a marker of activated macrophages) are greater in individuals with the IFNL3–IFNL4 risk haplotype that does not produce IFN-λ4, but produces IFN-λ3. No difference in these features was observed according to genotype at rs117648444, which encodes a substitution at position 70 of the IFN-λ4 protein and reduces IFN-λ4 activity, or between patients encoding functionally defective IFN-λ4 (IFN-λ4–Ser70) and those encoding fully active IFN-λ4–Pro70. The two proposed functional variants (rs368234815 and rs4803217)5,6 were not superior to the discovery SNP rs12979860 with respect to liver inflammation or fibrosis phenotype. IFN-λ3 rather than IFN-λ4 likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis., M.E., M.D., and J.G. are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney, and by a National Health and Medical Research Council of Australia (NHMRC) Program Grant (1053206) and NHMRC Project Grants (APP1107178 and APP1108422). G.D. is supported by an NHMRC Fellowship (1028432).

Published
2017
Full Text
View/download PDF

14. Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease

Author

Younes, Ramy, Rosso, Chiara, Gaggini, Melania, Mezzabotta, Lavinia, Marietti, Milena, Carli, Fabrizia, Salomone, Federico, Buzzigoli, Emma, Caviglia, Gian Paolo, Barbieri, Chiara, Abate, Maria Lorena, Smedile, Antonina, Saracco, Giorgio Maria, Anstee, Quentin M., Leeming, Diana J., Amalia Gastaldelli, Schuppan, Detlef, and Bugianesi, Elisabetta

Published
2017

15. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes

Author

Eslam, Mohammed, Mangia, Alessandra, Berg, Thomas, Chan, Henry Lik Yuen, Irving, William L., Dore, Gregory J., Abate, Maria Lorena, Bugianesi, Elisabetta, Adams, Leon A., Najim, Mustafa A. M., Miele, Luca, Weltman, Martin, Mollison, Lindsay, Cheng, Wendy, Riordan, Stephen, Fischer, Janett, Romero Gomez, Manuel, Spengler, Ulrich, Nattermann, Jacob, Rahme, Antony, Sheridan, David, Booth, David R., Mcleod, Duncan, Powell, Elizabeth, Liddle, Christopher, Douglas, Mark W., van der Poorten, David, George, Jacob, White, Rose, Rojas, Angela, Gallego Duran, Rocio, Bassendine, Margaret, Wong, Vincent W. S., Rosso, Chiara, Mezzabotta, Lavinia, Leung, Reynold, Malik, Barbara, Matthews, Gail, Applegate, Tanya, Grebely, Jason, Fragomeli, Vincenzo, Jonsson, Julie R., and Santaro, Rosanna

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Hepatitis, Viral, Human, Biology, Polymorphism, Single Nucleotide, Cohort Studies, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Internal medicine, Nonalcoholic fatty liver disease, medicine, Humans, Genetic Predisposition to Disease, Hepatitis, Hepatology, Membrane Proteins, Middle Aged, Viral Load, medicine.disease, Lipid Metabolism, Virology, Fibrosis, 030104 developmental biology, Liver, Case-Control Studies, Immunology, 030211 gastroenterology & hepatology, Female, Steatosis, Viral hepatitis, Viral load, TM6SF2
Abstract

A genome-wide exome association study has identified the transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 variant encoding an E167K substitution as a genetic determinant of hepatic steatosis in nonalcoholic fatty liver disease (NAFLD). The roles of this variant across a spectrum of liver diseases and pathologies and on serum lipids comparing viral hepatitis to NAFLD and viral load in chronic viral hepatitis, as well as its intrahepatic molecular signature, have not been well characterized. We undertook detailed analyses in 3260 subjects with viral and nonviral liver diseases and in healthy controls. Serum inflammatory markers and hepatic expression of TM6SF2 and genes regulating lipid metabolism were assessed in a subset with chronic hepatitis C (CHC). The rs58542926 T allele was more prevalent in 502 NAFLD patients than controls (P = 0.02) but not different in cohorts with CHC (n = 2023) and chronic hepatitis B (n = 507). The T allele was associated with alterations in serum lipids and hepatic steatosis in all diseases and with reduced hepatic TM6SF2 and microsomal triglyceride transfer protein expression. Interestingly, the substitution was associated with reduced CHC viral load but increased hepatitis B virus DNA. The rs58542926 T allele had no effect on inflammation, impacted ≥F2 fibrosis in CHC and NAFLD assessed cross-sectionally (odds ratio = 1.39, 95% confidence interval 1.04-1.87, and odds ratio = 1.62, 95% confidence interval 1.03-2.52, respectively; P0.03 for both), but had no effect on fibrosis progression in 1174 patients with CHC and a known duration of infection.The TM6SF2 E167K substitution promotes steatosis and lipid abnormalities in part by altering TM6SF2 and microsomal triglyceride transfer protein expression and differentially impacts CHC and chronic hepatitis B viral load, while effects on fibrosis are marginal. (Hepatology 2016;64:34-46).

Published
2016

16. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

Author

Thabet, Khaled, Asimakopoulos, Anastasia, Shojaei, Maryam, Romero Gomez, Manuel, Mangia, Alessandra, Irving, William L., Berg, Thomas, Dore, Gregory J., Grønbæk, Henning, Sheridan, David, Abate, Maria Lorena, Bugianesi, Elisabetta, Weltman, Martin, Mollison, Lindsay, Cheng, Wendy, Riordan, Stephen, Fischer, Janett, Spengler, Ulrich, Nattermann, Jacob, Wahid, Ahmed, Rojas, Angela, White, Rose, Douglas, Mark W., Mcleod, Duncan, Powell, Elizabeth, Liddle, Christopher, Van Der Poorten, David, George, Jacob, Eslam, Mohammed, Gallego Duran, Rocio, Applegate, Tanya, Bassendine, Margaret, Rosso, Chiara, Mezzabotta, Lavinia, Leung, Reynold, Malik, Barbara, Matthews, Gail, Grebely, Jason, Fragomeli, Vincenzo, Jonsson, Julie R., Santaro, Rosanna, Sydney Medical School Foundation, University of Sydney, National Health and Medical Research Council (Australia), Novo Nordisk Foundation, Danish Natural Science Research Council, German Research Foundation, The Hector Foundation, and Egypt Government

Subjects
0301 basic medicine, Liver Cirrhosis, Male, Genetics and Molecular Biology (all), Alcoholic liver disease, Cirrhosis, health care facilities, manpower, and services, General Physics and Astronomy, medicine.disease_cause, Biochemistry, Cohort Studies, Fibrosis, Genetics research, health care economics and organizations, Multidisciplinary, Fatty liver, Liver Neoplasms, Chemistry (all), Hepatitis C, Middle Aged, 3. Good health, Disease Progression, Female, medicine.symptom, Carcinoma, Hepatocellular, Science, Liver fibrosis, education, Inflammation, Polymorphism, Single Nucleotide, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, Physics and Astronomy (all), Immune system, medicine, Journal Article, Humans, business.industry, Membrane Proteins, General Chemistry, Hepatitis C, Chronic, Macrophage Activation, medicine.disease, Fatty Liver, Oxidative Stress, 030104 developmental biology, Case-Control Studies, Immune System, Immunology, Biochemistry, Genetics and Molecular Biology (all), business, Oxidative stress, Acyltransferases
Abstract

International Liver Disease Genetics Consortium., Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, a polymorphism in the MBOAT7 locus, as being associated with the development of alcoholic cirrhosis. Here we explore the role of this variant on liver inflammation and fibrosis in two cohorts of patients with chronic hepatitis C. In 2,051 patients, rs641738 associated with severe hepatic inflammation and increased risk of fibrosis, as well as fast fibrosis progression. At functional level, rs641738 associated with MBOAT7 transcript and protein levels in liver and blood, and with serum inflammatory, oxidative stress and macrophage activation markers. MBOAT7 was expressed in immune cell subsets, implying a role in hepatic inflammation. We conclude that the MBOAT7 rs641738 polymorphism is a novel risk variant for liver inflammation in hepatitis C, and thereby for liver fibrosis., M.E., M.W.D. and J.G. are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (1053206) and Project grants (APP1107178 and APP1108422). G.D. is supported by an NHMRC Fellowship (1028432). H.G. received support from The NOVO Nordisk Foundation the Danish Strategic Research Council (10-092797). U.S. and J.N. are supported by DFG SFB-TR57 and the Hector-Foundation (M63). K.T. is supported by Scholarship from the Egyptian government.

Published
2016
Full Text
View/download PDF

17. Clinical Patterns of hepatocellular carcinoma (HCC) in Non Alcoholic Fatty Liver Disease (NAFLD): a multicenter case-control study

Author

Piscaglia, F., Svegliati Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani e. gruppo studio italiano HCC NAFLD composto da: L. Bolondi, S. Bellentani e. gruppo studio italiano HCC NAFLD composto da: L. Bolondi, Zoli, M., Malagotti, D., Vanni, Ester, Mezzabotta, Lavinia, Cabibbo, G., Petta, S., Fracanzani, A., Fargion, S., Marra, F., Fani, B., Sacco, R., Morisco, F., Caporaso, N., Guarino, M., Colombo, M., D’Ambrosio, R., Crocè, L. S., Patti, R., Giannini, E., Lonardo, A., Baldelli, E., Miele, L., Grieco, A., Farinati, F., Pozzan, C., Borzio, M., Dionigi, E., Soardo, G., Roselli, P., Ciccarese, F., Virdone, F., Affronti, A., Boschi, F. G., Borzio, F., Trevisani, F., and Bugianesi, Elisabetta

Published
2015

21. Matabolomic analysis identifies new biomarkers of liver damage in NAFLD

Author

Vanni, Ester, Rosso, Chiara, Mezzabotta, Lavinia, Chiara, Saponaro, Melania, Gaggini, Gambino, Roberto, Ramy Ibrahim Kamal Jouness, Saba, Francesca, Emma, Buzzigoli, Fabrizia, Carli, Caviglia, GIAN PAOLO, Abate, Maria Lorena, Smedile, Antonina, Rizzetto, Mario, Cassader, Maurizio, Amalia, Gastaldelli, and Bugianesi, Elisabetta

Published
2014

22. Alteration in lipid metabolism after an oral fat load in patients with NAFLD

Author

Mezzabotta, Lavinia, Vanni, Ester, Rosso, Chiara, Gaggini, M., Gambino, Roberto, Buzzigoli, E., Saponaro, C., Ciociaro, D., Abate, Maria Lorena, Saba, F., Salomone, F., Caviglia, GIAN PAOLO, Carenzi, Silvia, Smedile, Antonina, Rizzetto, Mario, Cassader, Maurizio, Gastaldelli, A., and Bugianesi, Elisabetta

Published
2014

32. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease

Author

Rosso, Chiara, primary, Mezzabotta, Lavinia, additional, Gaggini, Melania, additional, Salomone, Federico, additional, Gambino, Roberto, additional, Marengo, Andrea, additional, Saba, Francesca, additional, Vanni, Ester, additional, Younes, Ramy, additional, Saponaro, Chiara, additional, Buzzigoli, Emma, additional, Caviglia, Gian Paolo, additional, Abate, Maria Lorena, additional, Smedile, Antonina, additional, Rizzetto, Mario, additional, Cassader, Maurizio, additional, Gastaldelli, Amalia, additional, and Bugianesi, Elisabetta, additional

Published
2015
Full Text
View/download PDF

33. Unexplained Common Bile Duct Dilatation With Normal Serum Liver Enzymes

Author

Bruno, Mauro, primary, Brizzi, Rosario F., additional, Mezzabotta, Lavinia, additional, Carucci, Patrizia, additional, Elia, Chiara, additional, Gaia, Silvia, additional, Mengozzi, Giulio, additional, Romito, Alessandrina V., additional, Eloubeidi, Mohamad A., additional, Rizzetto, Mario, additional, and De Angelis, Claudio, additional

Published
2014
Full Text
View/download PDF

35. Mo1471 Diagnosis and KI-67 Grading of Pancreatic Neuroendocrine Tumors (pNETs): Role and Accuracy of Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA)

Author

De Angelis, Claudio, primary, Pacchioni, Donatella, additional, Barreca, Antonella, additional, Carucci, Patrizia, additional, Bruno, Mauro, additional, Goss, Matteo Giuseppe, additional, Mezzabotta, Lavinia, additional, Marietti, Milena, additional, Manfrè, Selene F., additional, Sapino, Anna, additional, and Rizzetto, Mario, additional

Published
2014
Full Text
View/download PDF

38. Metabolomic analysis identifies new biomarkers of liver damage in NAFLD

Author

Vanni, Ester, Rosso, Chiara, Mezzabotta, Lavinia, Saponaro, Chiara, Gaggini, Melania, Gambino, Roberto, Jouness, Ramy Ibrahim Kamal, Saba, Francesca, Buzzigoli, Emma, Carli, Fabrizia, Caviglia, Gian Paolo, Abate, Maria Lorena, Smedile, Antonina, Rizzetto, Mario, Cassader, Maurizio, Amalia Gastaldelli, and Bugianesi, Elisabetta

40. Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease

Author

Rosso, Chiara, Vanni, Ester, Mezzabotta, Lavinia, Gambino, Roberto, Saba, Francesca, Salomone, Federico, Jouness, Ramy Ibrahim Kamal, Gaggini, Melania, Buzzigoli, Emma, Chiara Saponaro, Carli, Fabrizia, Caviglia, Gian Paolo, Abate, Maria Lorena, Smedile, Antonina, Rizzetto, Mario, Cassader, Maurizio, Gastaldelli, Amalia, and Bugianesi, Elisabetta

42. Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease

Author

Rosso, Chiara, Younes, Ramy, Carli, Fabrizia, Gaggini, Melania, Mezzabotta, Lavinia, Marietti, Milena, Salomone, Federico, Gambino, Roberto, Saba, Francesca, Buzzigoli, Emma, Ciociaro, Demetrio, Caviglia, Gian Paolo, Morello, Elisabetta, Abate, Maria Lorena, Smedile, Antonina, Ciancio, Alessia, Cassader, Maurizio, Saracco, Giorgio Maria, Amalia Gastaldelli, and Bugianesi, Elisabetta

43. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

Author

Thabet, Khaled, Asimakopoulos, Anastasia, Shojaei, Maryam, Romero-Gomez, Manuel, Mangia, Alessandra, Irving, William L., Berg, Thomas, Dore, Gregory J., Grønbæk, Henning, Sheridan, David, Abate, Maria Lorena, Bugianesi, Elisabetta, Weltman, Martin, Mollison, Lindsay, Cheng, Wendy, Riordan, Stephen, Fischer, Janett, Spengler, Ulrich, Nattermann, Jacob, Wahid, Ahmed, Rojas, Angela, White, Rose, Douglas, Mark W., McLeod, Duncan, Powell, Elizabeth, Liddle, Christopher, van der Poorten, David, George, Jacob, Eslam, Mohammed, Gallego-Duran, Rocio, Applegate, Tanya, Bassendine, Margaret, Rosso, Chiara, Mezzabotta, Lavinia, Leung, Reynold, Malik, Barbara, Matthews, Gail, Grebely, Jason, Fragomeli, Vincenzo, Jonsson, Julie R., Santaro, Rosanna, Thabet, Khaled, Asimakopoulos, Anastasia, Shojaei, Maryam, Romero-Gomez, Manuel, Mangia, Alessandra, Irving, William L., Berg, Thomas, Dore, Gregory J., Grønbæk, Henning, Sheridan, David, Abate, Maria Lorena, Bugianesi, Elisabetta, Weltman, Martin, Mollison, Lindsay, Cheng, Wendy, Riordan, Stephen, Fischer, Janett, Spengler, Ulrich, Nattermann, Jacob, Wahid, Ahmed, Rojas, Angela, White, Rose, Douglas, Mark W., McLeod, Duncan, Powell, Elizabeth, Liddle, Christopher, van der Poorten, David, George, Jacob, Eslam, Mohammed, Gallego-Duran, Rocio, Applegate, Tanya, Bassendine, Margaret, Rosso, Chiara, Mezzabotta, Lavinia, Leung, Reynold, Malik, Barbara, Matthews, Gail, Grebely, Jason, Fragomeli, Vincenzo, Jonsson, Julie R., and Santaro, Rosanna

Abstract

Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, a polymorphism in the MBOAT7 locus, as being associated with the development of alcoholic cirrhosis. Here we explore the role of this variant on liver inflammation and fibrosis in two cohorts of patients with chronic hepatitis C. In 2,051 patients, rs641738 associated with severe hepatic inflammation and increased risk of fibrosis, as well as fast fibrosis progression. At functional level, rs641738 associated with MBOAT7 transcript and protein levels in liver and blood, and with serum inflammatory, oxidative stress and macrophage activation markers. MBOAT7 was expressed in immune cell subsets, implying a role in hepatic inflammation. We conclude that the MBOAT7 rs641738 polymorphism is a novel risk variant for liver inflammation in hepatitis C, and thereby for liver fibrosis.

Full Text
View/download PDF

44. Pancreatic cancer imaging: the new role of endoscopic ultrasound.

Author

De Angelis C, Repici A, Carucci P, Bruno M, Goss M, Mezzabotta L, Pellicano R, Saracco G, and Rizzetto M

Subjects
Biopsy, Fine-Needle, Humans, Pancreatic Diseases pathology, Endosonography, Pancreatic Diseases diagnostic imaging
Abstract

Pancreatic cancer is the most deadly of all gastrointestinal malignancies and has a very poor prognosis. Unfortunately, most patients present late in the course of their disease and, at the time of diagnosis, only 10 to 25% of patients will be eligible for potentially curative resection. Efforts must be oriented towards an early diagnosis and towards reliably identifying patients who can really benefit from major surgery. A suspected pancreatic tumor can be a difficult challenge for the clinician. In the last ten years, we have witnessed notable technological improvements in radiological and nuclear imaging. Taking this into account, we will try to delineate the new role of endoscopic ultrasound (EUS) in pancreatic tumor imaging and to place EUS in a shareable diagnostic and staging algorithm. To date, the most accurate imaging techniques for pancreatic neoplasms remain contrast-enhanced computed tomography and EUS. EUS has the highest accuracy in detecting small lesions, in assessing tumor size and lymph node involvement, but helical CT must still be the first choice in patients with a suspected pancreatic tumor. However, after this first step, there is a place for EUS as a second diagnostic level in several cases: negative results on CT scan and persistent strong clinical suspicion of pancreatic cancer, doubtful results on CT scans or the need for cytohistological confirmation. In the near future, there will be great opportunities for the development of diagnostic and therapeutic EUS and pancreatic cancer could be the best testing ground.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results